Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drug Choice Particularly Important In Medicare Population – PhRMA Study

This article was originally published in The Pink Sheet Daily

Executive Summary

A PhRMA-sponsored study of ACE inhibitor, SSRI and insulin labels examined differences within the classes, including indication, route of elimination and interactions. Drug variations and characteristics of the elderly population make flexibility particularly important when designing formularies for the Medicare drug benefit, the study concludes.

You may also be interested in...



USP Draft Medicare Formulary Sets 146 Drug Categories And Classes

The proposed total is greater than the number of classes desired by PBMs but falls below the threshold drug manufacturers are seeking. Medicare Part D plans following the model formulary would have to offer at least two drugs in each therapeutic category and pharmacologic class.

USP Medicare Formulary Classes Should Use Mechanism Of Action, PhRMA Says

Subclasses should be based on other clinically relevant pharmacological characteristics, PhRMA tells USP pharmaceutical manufacturers forum. There should be enough classes to include the top 200 drugs for each of three Medicare subpopulations, PhRMA says.

Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal

A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060387

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel